New Parkinson's drug BIIB094 passes first safety test in small trial

NCT ID NCT03976349

Completed Disease control Sponsor: Ionis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety of a new drug called BIIB094 in 62 adults with Parkinson's disease. The drug was given as a spinal injection to see if it is safe and how the body processes it. The study included people with and without certain genetic variations. Results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BIIB094
What this could lead to: If successful, this could point toward a new treatment option for Parkinson's disease by targeting a genetic pathway.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (62 people) and may not lead to a working treatment. Side effects from the spinal injection are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE

Contacts and locations

Locations

Alliance for Multispecialty Research

Knoxville, Tennessee, 37920, United States
Hospital Clinic de Barcelona

Barcelona, 08036, Spain
Hospital General Universitario Gregorio Marañón

Madrid, 28007, Spain
Hospital General de Catalunya

Barcelona, Vizcaya, 08195, Spain
Inland Northwest Research

Spokane, Washington, 99202, United States
Laboratorios de Investigación Biocruces 3., Hospital de Cruces

Barakaldo, Bizkaia, 48903, Spain
Montreal Neurological Institute and Hospital

Montreal, Quebec, QC H3A 2B4, Canada
Neuro-SysMed Center

Bergen, 5053, Norway
Northwestern University PD and Movement Disorders Center

Chicago, Illinois, 60611, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Queen Square (Neurology) CRF Site Institute of Neurology & the National Hospital for Neurology and Neurosurgery UCLH

London, WC1N 3BG, United Kingdom
Quest Research Institute

Farmington Hills, Michigan, 48334, United States
Research Site

Toronto, Ontario, Canada
Research Site

Seville, Spain
Sourasky Medical Center

Tel Aviv, 64239, Israel
St. Olav University Hospital

Trondheim, 7030, Norway
The Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.